PR Newswire
Increased Domestic Production Guarantees Consistent Availability
NEWTOWN SQUARE, Pa. , June 18, 2024 /PRNewswire/ -- Kibow® Biotech has announced that its popular kidney health supplement, Renadyl™, is back in stock and will remain consistently available, due to expanded domestic manufacturing capabilities.
In response to the overwhelming demand from both doctors and patients worldwide, Kibow® Biotech has significantly increased its US-based production capacity. This enhancement ensures a consistent supply of Renadyl™, which has become a vital part of kidney health routines for many individuals managing the different stages of chronic kidney disease (CKD).
"We are proud to have Renadyl™ back in stock and in such high demand," said Michael Kane , Executive Vice President at Kibow® Biotech. And going forward, we are thrilled that our additional domestic manufacturing capabilities will be able to guarantee that Renadyl™ is always at its highest quality and in stock."
Kane added, "We understand the critical role Renadyl™ plays in supporting kidney health, and we sincerely apologize for any inconvenience caused by our recent inventory shortages."
Kibow® Biotech remains committed to empowering individuals with CKD to live life on their own terms. Renadyl™, the company's probiotic and prebiotic kidney health supplement, is demonstrated to support kidney function and improve overall well-being, offering a natural option for those seeking to support their kidney health.
Renadyl™ – the #1 nephrologist-recommended probiotic supplement for kidney health – is an all-natural, non-GMO, gluten-free, and non-prescription product available online throughout the US on Amazon and at Renadyl.com .
About Kibow® Biotech, Inc.: Kibow® Biotech specializes in research, development, and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. Founded October 1, 1997 , in Philadelphia, PA , the company's primary mission is to offer affordable, readily available, and easily administered nutritional supplements to support kidney health and other healthcare applications. Kibow® Biotech's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials has been published in peer-reviewed scientific/medical journals ( kibowbiotech.com/rd ), and the company's flagship product, Renadyl™, is marketed in the US, Canada , and several other countries as a kidney dietary supplement product in adherence with each country's governmental rules and regulatory authorities.
Contact Information:
Michelle Adams
President
PRISM Marketing
614-989-6373
michelle@prismmarketing.com
SOURCE Kibow Biotech